Been here since 7 months back, been watching posts from JP, Warp, Risk (from ihub days as well). Thank you everyone who contributes to DD here. Going to try and ask 'good' questions and contribute whenever I can here.
Are they calling it an 'interim analysis' because they are going to release the spec/sens results for only patients at site 1? Or do they need the data on the full sample size (72) to release any sort of data on how 'accurate' the test is?
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links